IL159551A0 - Stabilized oral suspension formulation - Google Patents

Stabilized oral suspension formulation

Info

Publication number
IL159551A0
IL159551A0 IL15955102A IL15955102A IL159551A0 IL 159551 A0 IL159551 A0 IL 159551A0 IL 15955102 A IL15955102 A IL 15955102A IL 15955102 A IL15955102 A IL 15955102A IL 159551 A0 IL159551 A0 IL 159551A0
Authority
IL
Israel
Prior art keywords
suspension formulation
oral suspension
stabilized oral
stabilized
formulation
Prior art date
Application number
IL15955102A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL159551A0 publication Critical patent/IL159551A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15955102A 2001-08-06 2002-08-05 Stabilized oral suspension formulation IL159551A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31037201P 2001-08-06 2001-08-06
PCT/US2002/024746 WO2003013473A1 (en) 2001-08-06 2002-08-05 Stabilized oral suspension formulation

Publications (1)

Publication Number Publication Date
IL159551A0 true IL159551A0 (en) 2004-06-01

Family

ID=23202195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15955102A IL159551A0 (en) 2001-08-06 2002-08-05 Stabilized oral suspension formulation

Country Status (33)

Country Link
US (2) US20030108575A1 (enExample)
EP (1) EP1414409B1 (enExample)
JP (1) JP2005500363A (enExample)
KR (1) KR20040025740A (enExample)
CN (1) CN1287768C (enExample)
AP (1) AP1817A (enExample)
AT (1) ATE353627T1 (enExample)
BR (1) BR0211736A (enExample)
CA (1) CA2454173A1 (enExample)
CO (1) CO5560559A2 (enExample)
CY (1) CY1106548T1 (enExample)
DE (1) DE60218175T2 (enExample)
DK (1) DK1414409T3 (enExample)
EA (1) EA007901B1 (enExample)
EC (1) ECSP044974A (enExample)
ES (1) ES2280560T3 (enExample)
GE (1) GEP20074027B (enExample)
HR (1) HRP20040118A2 (enExample)
IL (1) IL159551A0 (enExample)
IS (1) IS7126A (enExample)
MA (1) MA27054A1 (enExample)
MX (1) MXPA04001109A (enExample)
MY (1) MY135119A (enExample)
NZ (1) NZ530844A (enExample)
OA (1) OA12646A (enExample)
PL (1) PL366382A1 (enExample)
PT (1) PT1414409E (enExample)
SI (1) SI1414409T1 (enExample)
TN (1) TNSN04023A1 (enExample)
UA (1) UA80682C2 (enExample)
WO (1) WO2003013473A1 (enExample)
YU (1) YU7404A (enExample)
ZA (1) ZA200400639B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20050036956A1 (en) * 2003-08-15 2005-02-17 Lin Fei Non-aqueous liquid tooth whitening composition
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
PL2018153T3 (pl) * 2006-04-26 2012-09-28 Rosemont Pharmaceuticals Ltd Ciekłe kompozycje doustne
CN100434072C (zh) * 2006-06-19 2008-11-19 西安交通大学 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
EP2280697A1 (en) * 2008-04-30 2011-02-09 Wockhardt Research Centre Oral liquid compositions of rhein or diacerein
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
LT2544532T (lt) 2010-03-12 2017-06-12 Monsanto Technology Llc Agrocheminių gelių kompozicijos
JP6209446B2 (ja) * 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
KR102075173B1 (ko) * 2011-01-18 2020-02-07 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
WO2016196085A1 (en) * 2015-05-29 2016-12-08 Kiel Laboratories, Inc. Liquid formulations of celecoxib for oral administration
EP4353311A3 (en) 2015-07-20 2024-07-17 The Brigham and Women's Hospital, Inc. Shear-thinning compositions as an intravascular embolic agent
CN105902409B (zh) * 2016-05-13 2019-03-05 广东龙湖科技股份有限公司 一种温和且具有触变性的牙膏
CN109843331A (zh) * 2016-10-19 2019-06-04 萨恩帕斯药物有限公司 Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
CN112402376A (zh) * 2019-08-22 2021-02-26 上海上药信谊药厂有限公司 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法
CN117883379A (zh) * 2021-02-12 2024-04-16 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
KR20240161261A (ko) 2023-05-04 2024-11-12 주식회사 퍼슨 성상 안정성이 우수한 현탁액 조성물

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
AU639004B2 (en) * 1989-06-13 1993-07-15 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) * 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) * 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
JPH10507765A (ja) * 1994-10-27 1998-07-28 メルク フロスト カナダ インコーポレーテツド シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AU4479096A (en) * 1995-01-31 1996-08-21 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5596008A (en) * 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
AU708964B2 (en) * 1995-05-25 1999-08-19 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ATE247470T1 (de) * 1996-01-11 2003-09-15 Smithkline Beecham Corp Neue substituierte imidazolverbindungen
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5741798A (en) * 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en) * 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP0946507B1 (en) * 1996-12-10 2003-09-24 G.D. SEARLE & CO. Substituted pyrrolyl compounds for the treatment of inflammation
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) * 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100414998B1 (ko) * 1998-04-24 2004-01-13 머크 앤드 캄파니 인코포레이티드 Ｃｏｘ-2 억제제의 합성방법
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
WO2001030342A1 (en) * 1999-10-20 2001-05-03 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
DE60016191T2 (de) * 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
MXPA02010259A (es) * 2000-04-18 2003-12-11 Pharmacia Corp Formulacion de accion rapida de un inhibidor selectivo de ciclooxigenasa-2.
CA2415697A1 (en) * 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
GB0617119D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of prognosis

Also Published As

Publication number Publication date
UA80682C2 (en) 2007-10-25
EP1414409B1 (en) 2007-02-14
BR0211736A (pt) 2004-09-28
EA200400148A1 (ru) 2004-08-26
US20090081309A1 (en) 2009-03-26
EP1414409A1 (en) 2004-05-06
YU7404A (sh) 2006-08-17
MXPA04001109A (es) 2005-02-17
CN1549704A (zh) 2004-11-24
ATE353627T1 (de) 2007-03-15
IS7126A (is) 2004-01-26
GEP20074027B (en) 2007-02-12
CN1287768C (zh) 2006-12-06
CY1106548T1 (el) 2012-01-25
CO5560559A2 (es) 2005-09-30
MY135119A (en) 2008-02-29
HK1069542A1 (en) 2005-05-27
EA007901B1 (ru) 2007-02-27
DK1414409T3 (da) 2007-06-11
OA12646A (en) 2006-06-16
ZA200400639B (en) 2005-04-08
ECSP044974A (es) 2004-03-23
DE60218175D1 (de) 2007-03-29
CA2454173A1 (en) 2003-02-20
TNSN04023A1 (fr) 2006-06-01
SI1414409T1 (sl) 2007-06-30
JP2005500363A (ja) 2005-01-06
PL366382A1 (en) 2005-01-24
MA27054A1 (fr) 2004-12-20
US20030108575A1 (en) 2003-06-12
HRP20040118A2 (en) 2004-06-30
DE60218175T2 (de) 2007-11-22
KR20040025740A (ko) 2004-03-25
WO2003013473A1 (en) 2003-02-20
AP2004002969A0 (en) 2004-03-31
NZ530844A (en) 2005-11-25
AP1817A (en) 2008-01-07
PT1414409E (pt) 2007-03-30
ES2280560T3 (es) 2007-09-16

Similar Documents

Publication Publication Date Title
IL159551A0 (en) Stabilized oral suspension formulation
PL365518A1 (en) Oral composition
GB0319041D0 (en) Pharmaceutical Formulations
IL159532A0 (en) Enteral formulations
AU2003225444A1 (en) Oral suspension formulation
EP1407785A4 (en) MEDICAL COMPOSITIONS
HUP0400850A3 (en) Oral pharmaceutical compositions
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0106601D0 (en) Antiperspirant formulations
GB0126244D0 (en) Oral compositions
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0116945D0 (en) Antiperspirant formulations
GB0116946D0 (en) Antiperspirant formulations
GB0105560D0 (en) Pharmaceutical formulations
GB0111579D0 (en) Oral supplement
GB0125492D0 (en) Formulation
GB0110681D0 (en) Antiperspirant formulations
GB0124455D0 (en) Pharmaceutical formulations
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB0115893D0 (en) Formulations
GB0116619D0 (en) Formulation
GB0112497D0 (en) Formulation